How much is the market price of tremelimumab/box in 2024?

Tremelimumab/Tremelimumab (tremelimumab) is a cytotoxicT lymphocyte-associated antigen 4 (CTLA-4) blocking antibody, which can also be called an anti-tumor agent. Before treatment with tremelimumab, physicians will perform a pregnancy test in women of reproductive potential and also assess baseline liver enzymes, creatinine, adrenocorticotropic hormone levels, and thyroid function.

Tremelimumab can be used in combination with durvalumab to treat unresectable hepatocellular carcinoma (uHCC) in adults. It is designated as an orphan drug by the FDA, but the current US guidelines do not mention the use of tremelimumab alone to treat hepatocellular carcinoma. Tremelimumab may also be used in combination with durvalumab and platinum-based chemotherapy for the treatment of adults with metastatic non-small cell lung cancer in patients with tumor types that do not exhibit sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor abnormalities. The latest update to the ASCO Lifestyle Guidelines states that clinicians can offer durvalumab and tremelimumab plus platinum chemotherapy to patients with non-squamous or squamous cell carcinoma with a PD-L1 tumor proportion score of 0%-49% and a performance status of 0-1.

Tremelimumab/Tremelimumab is a new type of cancer immunotherapy drug. It has not yet been launched in China, so it cannot be included in the medical insurance. Domestic patients cannot yet purchase this drug. It is understood that the US version of temsitumumab original drug sold overseas may cost more than more than 3,000 US dollars per box, and the specification is 300mg/50mL (20mg/mL). The price is still relatively expensive. At present, we are not aware of the production and release of generic drugs of temsitumumab. For specific overseas prices and drug details, please consult Yaode Medical Consultants.